Elafin and secretory leukocyte protease inhibitor (SLPI) are two structurally related serine protease inhibitors present in the lung. The cellular origin of elafin in the alveolar space is unknown. It has been suggested that at least one alveolar leukocyte population express elafin. We therefore postulated that the alveolar macrophage, as the most numerous leukocyte in the alveolar space, express elafin. On the other hand, it is unclear whether human alveolar macrophages are a source of SLPI. In the present study, we showed by RT-PCR that human alveolar macrophages, but not peripheral blood monocytes, express elafin and SLPI tran scripts. Elafin, but not SLPI, m R N A expression was increased time dependently in alveolar macrophages stimulated with Saccharopolyspora rectivirgula antigen (50 ^ig/ml), a causative agent of hypersensitivity pneumonitis, but not LPS (10 ng/ml). Intracellular or cell-associated elafin protein accumulated after 24 h o f culture only in S. rectivirgula antigen-stimulated alveolar macrophages as shown by Western blot. In contrast, alveolar macrophages release 50 ± 6 pg/ml of SLPI in culture medium with no increase in function o f time. Alveolar macrophages could be a source of elafin in the lung. In addition to lung structural cells, SLPI could also be derived from alveolar macrophages.
Introduction
Elafin and secretory leukocyte protease inhibi tor (SLPI) are two structurally related low molec ular weight serine protease inhibitors that share a homologous four-disulfide bridge core harboring the antiprotease domain (Fritz, 1988; Molhuizen and Schalkwijk, 1995; Dijkman, 1995; Schalkwijk et al., 1999) . Elafin is a 6-kD elastase-specific in hibitor arising from the proteolytic cleavage of a 12-kD fully active precursor term ed pre-elafin or trappin-2. SLPI, also known as mucous protease inhibitor or antileukoprotease, is a broadspectrum serine protease inhibitor of 11.7 kD.
Both elafin and SLPI are present in the peri pheral lung where, together with o^-antitrypsin, they contribute to tightly regulate the destructive action of potent proteolytic enzymes, especially neutrophil elastase (Dijkman, 1995; Tremblay et al., 1996; McElvaney and Crystal, 1997; Senior and Anthonisen, 1998) . Beside their antiprotease ac tivity, elafin and SLPI are considered as im portant modulators of the host defence and inflammatory response. SLPI has antibacterial, antiviral, antifun gal and anti-inflammatory properties (Tomee et al., 1998; Grobm yer et al., 2000) . Elafin also has antimicrobial activity (Simpson et al., 1999) and could be involved in defence mechanisms against airborne bacteria (Suzuki et al., 2000) . Interest ingly, the expression of elafin and SLPI is dif ferentially regulated in the peripheral lung. For in stance, we have shown that elafin, but not SLPI, is overexpressed in farm er's lung, a form of hyper sensitivity pneumonitis (Tremblay et al., 1996) .
The cellular origin of elafin in the alveolar space is unknown (Schalkwijk et al., 1999) . In vitro studies suggest that elafin is produced by lung epi thelial-and Clara-like cells (Sallenave et al., 1993) , but this is not supported by immunohistochemical and in situ hybridisation studies on normal lung tissue (Molhuizen and Schalkwijk, 1995) . R e cently, Griese and colleagues suggested that at least one alveolar leukocyte population express elafin (Griese et al., 1997) . We postulated that al veolar macrophages, the most numerous leuko cytes in the alveolar space (M cLennan et al., 1996) , express elafin. The fact that alveolar macrophages are in a high state of activation in hypersensitivity (Selman, 1998) could explain the increased levels of elafin in bronchoalveolar la vage fluid from subjects with farmer's lung (Trem blay et al., 1996) . The concept that alveolar macro phages express serine protease inhibitors is not new. Indeed, these cells have been known for a while to express aj-antitrypsin (Mornex et al., 1986; Yuan et al., 1992) and a r antichymotrypsin (Nagareda et al., 1991) .
In the lung, SLPI has been localised in structural cells of the large conducting and small peripheral airways (Dijkman, 1995) . However, it is unclear whether human alveolar macrophages are also a source of SLPI (Griese et al., 1997) . While it is generally accepted that human macrophages (Song et al., 1999; Böhm et al., 1992) do not ex press this inhibitor, SLPI has been immunolocalised in macrophages of ovarian endometriomas (Suzumori et al., 1999) . In contrast to human SLPI, there is no doubt that this inhibitor is expressed in mouse (Jin et al., 1997; Jin et al., 1998; Kawai et al., 1999) and rat (Song et al., 1999; Gipson et al., 1999) cells of the monocytic lineage.
In the present study, we show that alveolar m a crophages express elafin and SLPI at both the mRNA and protein level. In contrast to SLPI, the expression of elafin is increased in alveolar m acro phages stimulated with Saccharopolyspora rectivirgula, a causative agent of farm er's lung. We con clude that alveolar macrophages could be a source of elafin in the lung. In addition to lung structural cells, SLPI could also be derived from alveolar m a crophages.
Materials and Methods

Isolation and stim ulation o f hum an alveolar m acrophages
Alveolar macrophages were obtained by bronchoalveolar lavage perform ed on normal nonsmoker volunteers using standard procedure (M cLennan et al., 1996) . All subjects gave a writ ten informed consent form and the local ethics committee approved the study. After centrifuga tion of bronchoalveolar lavage fluid, the cell pellet was washed with H anks' balanced salt solution (HBSS) and resuspended in RPMI 1640 medium with 10% fetal bovine serum (FBS; Gibco BRL, G rand Island, NY, USA). Total cell counts were determ ined with a hemocytometer and differential counts on Diff-Quik (Dade Diagnostics, Aguada, Puerto Rico) stained cytocentrifuge cell prepara tions. Alveolar m acrophages were purified by ad herence. Briefly, one million macrophages/well were dispensed into 24-well culture plates and in cubated for 1.5 h in RPM I 1640 medium (Gibco) containing 10% FBS (Gibco) at 37 °C under 95% air/5 % C 0 2. N on-adherent cells were removed by washing 4 times with HBSS. Purified alveolar m a crophages were either unstimulated or stimulated with 10 (ig/ml LPS (Sigma Chemical Co., St. Louis, MO, USA) (Sallenave et al., 1997a) or 50 ^xg/ml S. rectivirgula antigen (Tremblay et al., 1991) in RPM I 1640 medium with 10% FBS for up to 48 h at 37 °C under 95% air/5 % C 0 2.
Isolation o f hum an peripheral blood leukocytes
Heparinised venous blood was collected from healthy volunteers. A fter centrifugation and sedi m entation on 6% D extran (Am ersham Pharmacia Biotech, Uppsala, Sweden), monocytes/lympho cytes and granulocytes were purified from each other after a centrifugation on Ficoll-Paque (A m ersham Pharm acia Biotech). Monocytes were purified by adherence as for alveolar m acro phages. Eosinophils were separated from neutro phils by negative selection using a bead-conjugated m onoclonal anti-CD16 antibody and a magnetic cell sorter (Miltenyi Biotec Gm bH, Bergisch Gladbach, Germ any) as previously described (Laviolette et al., 1993) .
Reverse transcription -polym erase chain reaction (R T-P C R ) analysis
Total RNA was extracted from 6 -1 0 X 106 puri fied peripheral blood leukocytes and 1 -2 X 106 alveolar m acrophages using TRIzol reagent (Gibco) and a RNeasy Mini Kit (Qiagen Inc., Va lencia, CA, USA), respectively. The cDNA was synthesized by reverse transcription reaction of 1 |ig of RNA using Moloney M urine Leukemia Virus reverse transcriptase (Gibco). Expression of elafin, SPLI and control glyceraldehyde 3-phos phate dehydrogenase (G A PD H ) m RNA was then analyzed by PCR. The following mRNA-specific prim er pairs (Medicorp, Keystone Labs, Cam ar illo, CA, USA) were used: Elafin, sense: 5'-CA CG G G A G TTC CTG TTA A A G G -3' and anti sense: 5'-G A A C G A A A CA G G C C A TC CC G -3'; SLPI, sense: 5' -CATG A AGTCCAGCGGCCTCTT-3' and antisense 5 '-GGCAGGAATCAAGCTTTCACAG. The following GAPDH-specific primers were used as a positive control for each PCR reaction: sense: 5' -AGTCA A C G G ATTTGGT CGTAT-3', anti sense: 5' -TCTCGCTCCTGG A AG ATGG TG-3'. The PCR reaction was allowed to proceed for 30 cycles, each consisting of 30 s at 94 °C, 30 s at 60 °C, 60 s at 72 °C and finally a 10-min extension at 72 °C. A liquots of the PCR products were sepa rated on an 1% agarose gel. A 100-bp DNA ladder was included as a size marker. The elafin and SLPI PCR products were cloned into the pCR®2.1 vec tor (Invitrogen, Carlsbad, CA, USA) and their identity confirmed by sequencing (Service de se quence d 'ADN, Universite Laval, Quebec City, Canada).
M easure o f elafin and S L P I in alveolar m acrophage culture supernatant
Elafin in alveolar macrophage culture superna tant was m easured with a home-made ELISA as we described previously (Tremblay et al., 1996) . SLPI was m easured with an ELISA kit from R& D Systems (Minneapolis, MN, USA).
Electrophoresis and im m unoblotting o f elafin
Alveolar macrophages were directly hom ogen ised in non-reducing loading buffer. Protein analy sis by SDS-PAGE and immunoblotting on nitro cellulose membranes (Am ersham Pharmacia Biotech) were performed using standard methods with a rabbit anti-human elafin antiserum (Pep tides International, Inc., Louisville, KY, USA) as the first antibody as we described previously (Bourbonnais et al., 2000) . Chemiluminescence was detected using ECL reagent (Amersham Pharm acia Biotech).
Results
The expression of elafin and SLPI mRNA was evaluated by RT-PCR using mRNA-specific prim ers in alveolar macrophages. Both elafin and SLPI m RNA were constitutively expressed in alveolar macrophages from four different healthy subjects (Fig. 1) . The identity of the amplified PCR pro ducts was confirmed by an independent DNA se quencing service (data not shown). The next series of experim ent was perform ed to determ ine if this expression is upregulated in stimulated cells. To do so, alveolar m acrophages were exposed to either LPS (10 (ig /ml) or S. rectivirgula antigen (50 [ig/ ml) for increasing periods of time. As shown in Fig. 2 , elafin m RNA expression was increased time dependently in alveolar macrophages stimulated with S. rectivirgula antigen com pared to un stimulated cells. In contrast, LPS did not signifi cantly upregulate elafin expression. For identical experim ental conditions, there was no evident change in the expression of SLPI (data not shown).
Since S. rectivirgula antigen stimulated the ex pression of elafin m RNA in alveolar macrophages, we next investigated if this was also the case at the 
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protein level. While unstimulated and LPS-stimulated alveolar m acrophages showed undetectable levels of elafin protein as shown by Western blot, intracellular or cell-associated elafin protein accu mulated after 24 hours of culture in presence of S. rectivirgula antigen (Fig. 3) . As control, IL-lß-stimulated A549 human alveolar epithelial cells (Sallenave et al., 1994) showed detectable levels of elafin protein. Despite having shown the presence of intracellular or cell-associated elafin in S. rectiv/rgw/a-stimulated alveolar macrophages, we were unable to detect the protein even in concentrated cell culture supernatant. In contrast, unstimulated and S. recfrv/rgw/a-stimulated alveolar m acro phages released the same quantity of SLPI, namely 50 ± 6 pg/ml, in culture medium with no change in function of time.
Since the alveolar macrophage expresses elafin and SLPI, we were interested to show if its precur sor, i.e. peripheral blood monocyte, also expresses these serine protease inhibitors. Peripheral blood monocytes did not show detectable levels of either elafin or SLPI m RNA (Fig. 4) . As a positive con trol, we showed the expression of elafin and SLPI in peripheral blood neutrophils from the same subjects since these cells are known to express both inhibitors (Sallenave et al., 1997a) . Simulta neously, no elafin or SLPI transcripts were de tected in eosinophils from the same subjects. These observations were consistently repeated in peripheral blood leukocytes obtained from four healthy subjects. 
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Discussion
Elafin and SLPI are two low molecular weight serine protease inhibitors that, together with a r antitrypsin, protect the fragile lung architecture from proteolytic, especially elastolytic, damage (Dijkman, 1995; Tremblay et al., 1996; M cElvaney and Crystal, 1997; Senior and Anthonisen, 1998) . While CL}-antitrypsin is mainly synthesized by he patocytes (Perlmutter, 1993) and SLPI is locally produced by airway structural cells (Dijkm an, 1995) , the cellular origin of elafin in the lung is yet unknown (Schalkwijk et al., 1999) . As far as we know, all published in vivo studies failed to show elafin expression in lung structural cells. In light of a recent observation showing elafin expression in unpurified total bronchoalveolar lavage leuko cytes (Griese et al., 1997) , we postulated that alve olar macrophages are the leukocyte expressing elafin in the peripheral lung. A t the same time, we wanted to definitively settle the controversy whether human macrophages express (Suzumori et al., 1999) or not (Griese et al., 1997; Song et al., 1999; Böhm et al., 1992) SLPI.
We showed that alveolar macrophages constitutively express both elafin and SLPI mRNA. H ow ever, elafin and SLPI expression is differently reg ulated in these cells. Elafin, but not SLPI, m RNA levels were increased in alveolar macrophages stimulated with S. rectivirgula. This therm oactinomycete is a causative agent of farmer's lung, a form of hypersensitivity pneumonitis (Corm ier and Schuyler, 1992) . Interestingly, we already showed that, in contrast to SLPI, elafin levels are increased in bronchoalveolar lavage fluid of sub jects with this lung disease (Tremblay et al., 1996) . This strongly suggests that alveolar macrophages, but not alveolar epithelial cells, are the cellular source of elafin in farm er's lung. Supporting this concept is our observation that elafin expression in A549 lung epithelial cells, a cell line known to express this inhibitor in vitro (Sallenave et al., 1993) , is not increased by S. rectivirgula (Bingle C. D., Bingle L. and Tremblay G. M., unpublished results) . A discordant note is that we only showed intracellular or cell-associated elafin protein ex pression in alveolar macrophages being unable to detect any elafin protein in cell culture superna tant. This suggests that an additional triggering sig nal is required to make alveolar macrophages ex ternalise elafin.
The results of the present study shed a new light on the controversy whether human macrophages express SLPI. There is a common belief that hu man macrophages do not express SLPI (Griese et al., 1997; Song et al., 1999; Böhm et al., 1992) . In contrast to Griese and colleagues, who were un able to detect SLPI transcripts in bronchoalveolar lavage cells (Griese et al., 1997) , we found that alveolar macrophages express SLPI mRNA. The discrepancy between the two studies could be ex plain by the fact that the cells used in the former study (Griese et al., 1997) were obtained from pre term neonates of less than 30 weeks gestation, while we used cells from adult subjects. This could m ean that SLPI expression in human alveolar m a crophages is developmentally regulated as for other functional activities (Sherman, 1997) . Not only alveolar macrophages from normal volun teers express SLPI mRNA, but these cells in cul ture release about 50 pg/ml/106 cells/24 h, a value that is the same as the one recently reported as an abstract by Takeyabu and colleagues (Takeyabu et al., 2000) .
Having shown that alveolar macrophages ex press elafin and SLPI, we performed a RT-PCR on purified peripheral blood monocytes from normal subjects. Like others (Böhm et al., 1992; Griese et al., 1997; Song et al., 1999) , we did not observe any detectable level of either elafin of SLPI transcripts in these cells. O ur results and those from others m entioned above suggest that SLPI expression is the privilege of macrophages, but not monocytes.
Compellingly, a thorough reading of the litera ture shows that SLPI expression has been de m onstrated in rat and mouse macrophages, but not monocytes, in all (Jin et al., 1997; Jin et al., 1998; Kawai et al., 1999; Gipson et al., 1999) but one (Song et al., 1999) study. Even in this latter study, rat SLPI m RNA was present at very high levels in peritoneal macrophages, but close to absent in resting peripheral blood monocytes. In contrast to monocytes, purified neutrophils from the same subjects clearly express both inhibitors as previously reported by others (Böhm et al., 1992; Sallenave et al., 1997a) , while eosinophils do not.
To the best of our knowledge, the present study provides the first evidence that human alveolar macrophages express elafin and SLPI. Such ex pression may be physiologically highly relevant. First, expression of elafin and SLPI in alveolar m a crophages may constitute a first wave of elastase defence, while inhibitor generation by lung struc tural cells, including SLPI (Dijkman, 1995) and 0^-antitrypsin (Sallenave et al., 1997b) , act as a se cond wave as suggested by a recent study (Gipson et al., 1999) . Second, elafin and SLPI may be con sidered as members of the hum an alveolar m acro phage arm am entarium against airborne pathogens considering their antimicrobial properties (Tomee et al., 1998; Simpson et al., 1999) . Third, elafin and SLPI expression may suppress alveolar m acro phage inflammatory functions by an autocrine mechanism. Indeed, SLPI upregulates the pro duction of IL-10 and TGFß, two anti-inflamma tory cytokines, in m acrophages (Sano et al., 2000) , interferes with the prostaglandin E 2-dependent production of m etalloproteases in monocytes (Zhang et al., 1997) , and suppresses the production of nitric oxide and T N F a in SLPI-transfected m a crophages (Jin et al., 1997) . We are currently inves tigating w hether elafin also shows such anti-in flammatory activities on macrophages.
Regulatory mechanisms orchestrating the ex pression of serine protease inhibitors in alveolar macrophages and lung structural cells are, most than likely, complex. For instance, alveolar m acro phages respond to S. rectivirgula antigen by increasing elafin, but not SLPI, expression (this study), while oncostatin M specifically stimulates ai-antitrypsin in alveolar epithelial cells (Sallen ave et al., 1997b) . F urther studies are under way to identify specific triggering signals for elafin and SLPI expression in alveolar macrophages.
